Abstract
Background and objectiveRisk stratification of head and neck cancer (HNC) patients is important to settle individualized treatment strategies. This study proposed a multi-level fusion graph neural network (MLF-GNN) that fuses PET/CT image features and clinical data for improved prognosis prediction of HNC patients. MethodsThis study exploited 642 HNC patients from 7 different centers collected from The Cancer Imaging Archive (TCIA), which were arbitrarily separated into 507 patients from 4 centers for training and internal validation, and 135 patients from 3 centers for external testing. We constructed a population graph with edges representing the similarity between patients and the vertices representing radiomics features. Single-modality GNN models and MLF-GNN models by using feature-fusion and network-fusion strategies were constructed for progression-free survival (PFS) prediction, respectively. Model performance was evaluated by the concordance index (C-index), area under the receiver operator characteristic curve (ROC-AUC), and Kaplan–Meier curves. ResultsCompared with the single-modality GNN models and feature-fusion based MLF-GNN model, the network-fusion based MLF-GNN model achieved the highest C-index of 0.788 (95 % CI: 0.727–0.848) and AUC of 0.807 (95 % CI: 0.731–0.870) for PFS prediction in the external testing set. Besides, it also showed good performance on the secondary endpoints of overall survival (OS), recurrence-free survival (RFS), and metastasis-free survival (MFS) in the external testing set, with C-index of 0.800 (95 % CI: 0.729–0.871), 0.823 (95 % CI: 0.763–0.884) and 0.758 (95 % CI: 0.673–0.844), respectively. Subgroup analysis stratified with pathogenic site and treatment type showed that the proposed method has good prediction performance on subgroup risk stratification. ConclusionsThe proposed MLF-GNN model could capture the topological relationships among patients by taking full advantage of multi-modality imaging data and clinical data, which achieved improved prognostic performance and was beneficial to guide individual treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.